Rh-endostatin in combination with docetaxel and carboplatin as adjuvant treatment for non-small lung cancer

Daliang Qi, Yan Zhuo Yang, Zhu Jun Liu, Qing Sheng Wang, Liang Xin, Yan Cui, Yu Feng Qiao, Kui Feng

    Research output: Contribution to journalArticle

    2 Scopus citations


    Objective: To evaluate the efficacy of Endostar™ (rh-endostatin, YII-16) combined with docetaxel and carboplatin (TP) regimen for the adjuvant treatment of non-small lung cancer (NSCLC) and its impact on circulating blood markers. Methods: 36 patients with stage I b- III a postoperative NSCLC, were randomly divided into the treatment group, Endostar™ plus TP regimen, and the control group, TP regimen only, respectively. DFS and toxicities of patients were observed. The numbers of CEC and the levels of tumor marker CEA, NSE and CYFR21-1 were measured. Results: The numbers of CEC and the levels of CEA, NSE and CYFR21-1 decreased after treatment. There were significant differences in CEC and NSE between treatment group and control group after four cycles of treatment, respectively (P = 0.016 and 0.013). Disease-free survival time (DFS) was longer in treatment group than control group but without significant difference. CEC was significantly increased in recurrent and metastasis cases and decreased after effective treatment. Conclusion: Endostar™ combined with TP regimen seem to be superior to TP alone in some short term index for the treatment of postoperative NSCLC even though long-term survival is still anticipated. CEC, as a biomarker, may be useful in predicting the efficacy of the such synergistic treatment.

    Original languageEnglish (US)
    Pages (from-to)1057-1059
    Number of pages3
    JournalNational Medical Journal of China
    Issue number15
    StatePublished - Apr 21 2009



    • Carboplatin
    • Carcinoma, non-small-cell lung
    • Drug therapy, combination
    • Rh-endostatin

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this